Yoshihiro Fujimura Selected Research

Rituximab (Mabthera)

8/2016	Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.
1/2013	[Case report; successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura].
10/2008	Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.
2/2007	[Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine].
12/2006	[Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].
6/2005	Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshihiro Fujimura Research Topics

Disease

55	Thrombotic Thrombocytopenic Purpura 01/2019 - 01/2002
16	Thrombocytopenia (Thrombopenia) 11/2020 - 05/2006
14	Thrombotic Microangiopathies 01/2019 - 12/2003
13	Thrombosis (Thrombus) 07/2019 - 03/2002
12	Atypical Hemolytic Uremic Syndrome 01/2022 - 01/2014
10	Hemolytic-Uremic Syndrome 05/2011 - 01/2002
9	acquired Thrombotic thrombocytopenic purpura 08/2016 - 03/2002
6	Renal Insufficiency (Renal Failure) 08/2016 - 01/2005
5	Disease Progression 10/2018 - 01/2005
5	Hemolytic Anemia 07/2017 - 12/2006
4	Hemorrhage 01/2017 - 01/2002
4	Hemolysis 12/2016 - 02/2007
4	Liver Diseases (Liver Disease) 07/2015 - 08/2005
4	Infections 01/2014 - 10/2007
4	Connective Tissue Diseases (Connective Tissue Disease) 01/2013 - 08/2009
3	Sepsis (Septicemia) 01/2021 - 10/2007
3	Neoplasms (Cancer) 07/2015 - 01/2004
3	Acute Kidney Injury (Acute Renal Failure) 04/2015 - 05/2013
3	Fever (Fevers) 01/2013 - 12/2006
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 02/2007
2	Inflammation (Inflammations) 07/2019 - 06/2009
2	Purpura 06/2018 - 10/2007
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2018 - 03/2002
2	Hepatitis 09/2017 - 01/2010
2	Hypertension (High Blood Pressure) 04/2015 - 01/2013
2	Fetal Death 01/2014 - 03/2009
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2011 - 08/2009
2	Alcoholic Hepatitis 02/2010 - 01/2007
2	Lymphoma (Lymphomas) 10/2008 - 11/2006
1	Cytokine Release Syndrome 04/2022
1	COVID-19 04/2022
1	Thromboinflammation 04/2022
1	Disseminated Intravascular Coagulation 04/2020
1	Rare Diseases (Rare Disease) 10/2019
1	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 07/2019
1	Meningococcal Infections 01/2019
1	Cerebral Infarction 12/2018
1	Pathologic Constriction (Stenosis) 12/2018
1	Transfusion Reaction 11/2018
1	Macular Degeneration (Age-Related Maculopathy) 01/2018
1	HELLP Syndrome 09/2017
1	Multiple Organ Failure (MODS) 09/2017
1	Hyperbilirubinemia 12/2016

Drug/Important Bio-Agent (IBA)

47	thiamine triphosphorate (TTP)IBA 10/2019 - 03/2002
18	von Willebrand FactorIBA 07/2019 - 02/2003
10	ADAMTS13 ProteinIBA 02/2007 - 01/2002
8	AntigensIBA 04/2022 - 01/2007
8	Metalloproteases (Metalloproteinases)IBA 09/2017 - 10/2004
6	AutoantibodiesIBA 01/2022 - 01/2002
6	ThrombospondinsIBA 09/2017 - 10/2004
6	Rituximab (Mabthera)FDA Link 08/2016 - 06/2005
5	Complement System Proteins (Complement)IBA 01/2022 - 11/2014
5	eculizumab FDA Link 01/2019 - 04/2015
5	Pharmaceutical PreparationsIBA 01/2013 - 01/2005
5	DisintegrinsIBA 01/2013 - 10/2004
5	Immunoglobulin G (IgG)IBA 01/2011 - 03/2002
4	AntibodiesIBA 11/2020 - 01/2015
3	Interleukin-8 (Interleukin 8)IBA 04/2022 - 02/2010
3	Complement Factor H (Factor H)IBA 01/2022 - 04/2015
3	SteroidsIBA 04/2015 - 01/2005
3	Ticlopidine (Ticlid)FDA LinkGeneric 06/2013 - 02/2009
3	Clopidogrel (Plavix)FDA Link 11/2012 - 10/2007
3	CollagenIBA 09/2012 - 02/2003
3	EnzymesIBA 09/2002 - 01/2002
2	Dacarbazine (DIC)FDA LinkGeneric 04/2020 - 11/2006
2	Intravenous Immunoglobulins (IVIG)FDA Link 07/2019 - 02/2007
2	Shiga Toxin (Shigella Toxin)IBA 06/2018 - 04/2015
2	Monoclonal AntibodiesIBA 11/2017 - 02/2008
2	EndotoxinsIBA 09/2017 - 02/2010
2	InterleukinsIBA 09/2017 - 02/2010
2	CytokinesIBA 09/2017 - 02/2010
2	ThrombomodulinIBA 04/2015 - 01/2013
2	Bevacizumab (Avastin)FDA Link 01/2015 - 01/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2013 - 02/2010
2	Indicators and Reagents (Reagents)IBA 07/2012 - 01/2008
2	triphosphoric acid (triphosphate)IBA 06/2009 - 02/2005
2	Messenger RNA (mRNA)IBA 06/2009 - 08/2005
2	thienopyridineIBA 02/2009 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 09/2008 - 08/2005
1	FibrinIBA 04/2022
1	Interleukin-6 (Interleukin 6)IBA 04/2022
1	Thromboplastin (Tissue Factor)IBA 04/2022
1	Human Platelet AntigensIBA 11/2020
1	Immunoglobulins (Immunoglobulin)IBA 11/2018
1	Immunoglobulin E (IgE)IBA 11/2018
1	afliberceptIBA 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	antineoplaston A10 (A 10)IBA 11/2017
1	Oxygen (Dioxygen)IBA 12/2016

Therapy/Procedure

12	Plasma Exchange 12/2018 - 05/2002
11	Therapeutics 12/2016 - 12/2002
4	Liver Transplantation 07/2015 - 12/2003
3	Drug Therapy (Chemotherapy) 01/2015 - 10/2008
3	Transplantation 01/2014 - 05/2006
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2021 - 01/2017
2	Plasmapheresis 01/2017 - 12/2006
2	Hepatectomy 07/2015 - 03/2010
2	Peritoneal Dialysis 04/2015 - 02/2007
1	Intravitreal Injections 01/2018
1	Blood Transfusion (Blood Transfusions) 12/2016